Login / Signup

Questioning the Design of Non-Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials.

Florian LemaitreSébastien LalanneMarie-Clémence Verdier
Published in: Clinical pharmacology and therapeutics (2024)
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • phase ii
  • placebo controlled